Drugs / KH903
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04555304 | Sep 2020 → Jan 2022 | gastric cancer, gastroesophageal cancer | Chengdu Kanghong Biotech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KH903 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04555304 ↗ |
| Route | Intravenous | “KH903 4 mg/kg will be administered intravenously” NCT04555304 ↗ |